| WXIBF Stock | | | USD 1.86 0.00 0.00% |
CEO
Dr. Zhisheng Chen was appointed as Chief Executive Officer, Executive Director of the Company. He was appointed as an executive Director and chief executive officer in February 2014 and January 2016, respectively. He is also the chairman of the Strategy Committee of the Company. Dr Chen is primarily responsible for the overall management of the business of the Group. He joined the Group in June 2011 and also serves as a director of most subsidiaries of the Company. From June 2011 to January 2016, Dr. Chen served as a senior vice president of WuXi AppTec Co., Ltd., and was responsible for the management of biologics development and manufacturing. From August 2008 to June 2011, Dr. Chen served as the chief operating officer of Shanghai Celgen Bio Pharmaceutical Co., Ltd., and was responsible for the development, manufacturing and quality control of biologics. From November 2005 to August 2008, Dr. Chen served as a director and senior engineering consultant of Eli Lilly and Company, a global pharmaceutical company listed on NYSE, and was responsible for running a clinical manufacturing facility and providing technical guidance to biologics development and manufacturing. From June 2000 to November 2005, Dr. Chen served as a process engineer and manager of Merck Co. Inc., a pharmaceutical company listed on NYSE, and was responsible for providing technical support and troubleshooting manufacturing issues of biologics and recombinant vaccines since 2016.
| Age | 50 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 86 510 8183 1205 |
| Web | https://www.wuxibiologics.com |
Chen obtained a bachelor’s degree in chemical engineering from Tsinghua University in June 1994 and a Ph.D. degree in chemical engineering from University of Delaware in June 2000.
WuXi Biologics Management Efficiency
The company has return on total asset
(ROA) of
0.0551 % which means that it generated a profit of $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.123 %, meaning that it generated $0.123 on every $100 dollars invested by stockholders. WuXi Biologics' management efficiency ratios could be used to measure how well WuXi Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
WuXi Biologics has accumulated 640.51
M in total debt with debt to equity ratio
(D/E) of 0.12, which may suggest the company is not taking enough advantage from borrowing. WuXi Biologics has a current ratio of 2.25, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist WuXi Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, WuXi Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like WuXi Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for WuXi to invest in growth at high rates of return. When we think about WuXi Biologics' use of debt, we should always consider it together with cash and equity.
WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States. WuXi Biologics [WXIBF] is a
Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.
Management Performance
WuXi Biologics Leadership Team
Elected by the shareholders, the WuXi Biologics' board of directors comprises two types of representatives: WuXi Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of WuXi. The board's role is to monitor WuXi Biologics' management team and ensure that shareholders' interests are well served. WuXi Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, WuXi Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| He Wang, VP Officer | |
| Eileen Wang, IR Senior Director | |
| Weichang Zhou, Senior Vice President CTO, Executive Director | |
| Ming Tu, CFO VP | |
| Li Xiong, VP HR | |
| Ge Li, Non-Executive Chairman of the Board | |
| Jijie Gu, Ex Officer | |
| Zhisheng Chen, CEO, Executive Director | |
| Cong JD, VP Department | |
| Tang MBA, Operations, Communications | |
WuXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is WuXi Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in WuXi Pink Sheet
WuXi Biologics financial ratios help investors to determine whether WuXi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WuXi with respect to the benefits of owning WuXi Biologics security.